Aqualane Clinical Research
Aqualane Clinical Research
Naples, Florida, United States23 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis | CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Recruiting | Phase 3 | 2026-10-07 | NCT07299019 | |
| A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-10-07 | NCT06653153 | |
| A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-10-05 | NCT06793397 | |
| A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity | CNS demyelinating autoimmune disease, Muscle Hypertonia, Muscle Spasticity, Neurologic Manifestations, Neuromuscular Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, muscle tissue disorder, musculoskeletal system disorder, nervous system disorder | Recruiting | Phase 2 | 2026-10-01 | NCT06782490 | |
| A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Phase 1 | 2026-10-01 | NCT06565195 | |
| Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-09-25 | NCT06559306 | |
| A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic inflammatory demyelinating polyradiculoneuropathy, demyelinating disease, immune system disorder, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, polyneuropathy, polyradiculoneuropathy | Recruiting | Phase 3 | 2026-09-24 | NCT07091630 | |
| Randomized Study in Children and Adolescents With Migraine: Acute Treatment | Ear Diseases, Nausea, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Photophobia, Sensation Disorders, Signs and Symptoms, Signs and Symptoms, Digestive, brain disorder, central nervous system disorder, eye disorder, headache disorder, hearing disorder, hyperacusis, hypnic headache, migraine disorder, nervous system disorder, otorhinolaryngologic disease, vision disorder | Recruiting | Phase 3 | 2026-09-24 | NCT04649242 | |
| Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis | Active, not recruiting | Phase 3 | 2026-09-22 | NCT06700343 | |
| A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | Alzheimer disease, Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-09-22 | NCT06585787 | |
| Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | Relapsing Multiple Sclerosis | Recruiting | Phase 3 | 2026-08-26 | NCT06846281 | |
| Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2) | Charcot-Marie-Tooth disease type 1F, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Active, not recruiting | Phase 3 | 2026-08-18 | NCT05156281 | |
| Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab | Relapsing Multiple Sclerosis (RMS) | Active, not recruiting | Phase 3 | 2026-08-10 | NCT06869785 | |
| A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis | CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Recruiting | Phase 3 | 2026-07-29 | NCT07225504 | |
| A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-07-27 | NCT07115329 | |
| Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy | Diabetic Peripheral Neuropathic Pain | Recruiting | Phase 3 | 2026-07-20 | NCT07231419 | |
| A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Active, not recruiting | Phase 3 | 2026-07-08 | NCT05070858 | |
| A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD) | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 1 | 2026-06-04 | NCT06657768 | |
| Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS | Relapsing Multiple Sclerosis | Active, not recruiting | Phase 3 | 2026-05-27 | NCT03650114 | |
| A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis | Acute Gastroenteritis; Norovirus Acute Gastroenteritis | Active, not recruiting | Phase 3 | 2026-05-13 | NCT06592794 | |
| A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Phase 1 | 2026-04-20 | NCT06809400 | |
| A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 1 / Phase 2 | 2026-02-11 | NCT07250750 | |
| Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy | autonomic nervous system disorder, basal ganglia disorder, brain disorder, cardiovascular disorder, central nervous system disorder, hypotensive disorder, movement disorder, multiple system atrophy, nervous system disorder, primary dysautonomia, vascular disorder | Active, not recruiting | Phase 3 | 2025-09-05 | NCT05696717 |